Incyte (NASDAQ:INCY) was downgraded by analysts at Gabelli from a “buy” rating to a “hold” rating in a research note issued on Monday, The Fly reports.
Other research analysts have also issued reports about the stock. Nomura restated a “buy” rating on shares of Incyte in a report on Thursday, February 1st. Oppenheimer set a $65.00 price target on shares of Incyte and gave the stock a “hold” rating in a research note on Monday. BMO Capital Markets reiterated a “buy” rating and issued a $172.00 price target on shares of Incyte in a research note on Wednesday, January 3rd. William Blair reiterated a “market perform” rating on shares of Incyte in a research note on Friday. Finally, ValuEngine upgraded shares of Incyte from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Three analysts have rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Incyte presently has a consensus rating of “Buy” and an average target price of $127.50.
Shares of NASDAQ INCY opened at $64.02 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.01 and a quick ratio of 3.99. Incyte has a 12 month low of $63.43 and a 12 month high of $142.45. The firm has a market capitalization of $13,559.35, a price-to-earnings ratio of 100.03 and a beta of 0.66.
Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.54. Incyte had a negative net margin of 20.38% and a negative return on equity of 11.85%. The business had revenue of $444.20 million during the quarter, compared to analyst estimates of $435.23 million. During the same period in the prior year, the business earned $0.05 EPS. The company’s revenue for the quarter was up 36.0% on a year-over-year basis. equities research analysts expect that Incyte will post -0.28 EPS for the current year.
In related news, insider David W. Gryska sold 1,952 shares of the stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $85.56, for a total transaction of $167,013.12. Following the sale, the insider now directly owns 12,922 shares of the company’s stock, valued at approximately $1,105,606.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Reid M. Huber sold 1,958 shares of the stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $85.55, for a total transaction of $167,506.90. The disclosure for this sale can be found here. Corporate insiders own 17.20% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Financial Gravity Companies Inc. purchased a new stake in Incyte during the 4th quarter valued at about $120,000. Private Advisor Group LLC purchased a new stake in Incyte during the 3rd quarter valued at about $203,000. Advantage Investment Management LLC grew its position in Incyte by 1,233.3% during the 4th quarter. Advantage Investment Management LLC now owns 2,000 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 1,850 shares during the last quarter. Griffin Asset Management Inc. purchased a new stake in shares of Incyte during the 4th quarter valued at about $200,000. Finally, Caxton Associates LP purchased a new stake in shares of Incyte during the 3rd quarter valued at about $257,000. 93.50% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Gabelli Downgrades Incyte (INCY) to Hold” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/09/gabelli-downgrades-incyte-incy-to-hold.html.
Incyte Company Profile
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.